 Recently commercially available new-DES, zotarolimus-eluting stent ZES demonstrated significant reduction of restenosis and cardiac events during 9-month. However, it has not been tested that 8-month treatment of cilostazol also effectively inhibits the neointimal hyperplasia after ZES implantation in patients with long coronary lesions. Therefore, to evaluate whether the cilostazol reduce neointimal hyperplasia after ZES implantation, the investigators performed double-blind, randomized, multicenter, prospective study compared triple antiplatelet therapy aspirin plus clopidogrel plus cilostazol and dual antiplatelet therapy aspirin plus clopidogrel for 8 months in patients with long coronary lesion treated with ZES. 